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CLINICAL TRIAL OF A NEW SULPHONYLUREA IN MATURITY-ONSET DIABETES-
HB419 (GLIBENCLAMIDE)*
H. c. SEFTEL, B.Sc., M.B., B.CH., DIP. MED. (RAND), Department of Medicine, Johannesburg Non-European
Hospital and University of the Witwatersrand. Johannesburg
In this paper is reported a trial of a new oral sulphonyl-
urea, HB419 or glibenclamide, in the treatment of
maturity-onset diabetes. Chemically the substance is N-
{ 4-(f3[2-methoxy-5-chlorobenzamidoJ-ethyl)-benzosulfonyl}






Fig. 1. Structural formula of glibehclamide.
In animal experiments it has been shown to be an
extremely powerful hypoglycaemic agent; administered
intravenously to normal dogs it was 440 times more active
than tolbutamide on a molar basis.' Several workers have
shown that HB419 stimulates the release of insulin from
human beta cells.'" In non-diabetic human subjects the
duration of action of the compound varies with dosage,
being about 8 hours after a single dose of 2 mg. and up
to 12 hours or longer after 5 mg:
In man the biologic half-life in plasma is 5 - 7 hours.
After oral administration about 25% is excreted in the
urine, mainly in oxidized form, and about 75% is ex-
creted unchanged in the faeces: Acute and chronic
toxicity studies in animals, including tests of teratogeni-
city, revealed a high degree of safety: The agent has no
antibacterial properties:
PATIENTS AND METHODS
Eighty-six maturity-onset diabetics were treated at Johan-
nesburg Non-European Hospital on an outpatient basis.
There were 54 Indians (28 males and 26 females) who
were mainly Moslems, and 32 Bantu (8 males and 24 fe-
males). Their ages ranged from 29 to 75 years, with three-
quarters of the patients between 40 and 60 years. The
majority were overweight. The standards of education and
literacy of both Indian and Bantu patients were generally
low. The Indians were considerably more affluent than
the Bantu, but in both groups it was difficult to impose
and maintain a strict dietary regimen, and in the majority
of patients the caloric intake was excessive. About one-
third of the diabetics were new, while in two-thirds the
disease was of variable duration and had been treated
previously with other oral agents, mostly sulphonylureas.
A number of patients were referred to the hospital by
general practitioners because of difficulty in controlling
the disease.
New diabetics were started on one tablet (5 mg.) of
HB419 daily after it had been established that control by
'Date received: 2 June 1969.
diet alone was inadequate. Patients previously on tolbuta-
mide were also first tried on one tablet daily, while those
on chlorpropamide were usually given the ame number
of tablets that they were already taking.
HB419 was usually taken as a single dose at breakfast,
but some patients on more than two tablets daily took
the drug 2 or 3 times a day. The duration of treatment
was variable: 1 patient received HB419 for 1 week, 14
patients were treated for 1 - 2 months, 9 for 3 - 4 months,
14 for 5 - 6 months, 13 for 7 - 8 months, 18 for 9 - 10
months and 17 for 11 - 12 months.
Patients were seen at weekly intervals to begin with,
then fortnightly and thereafter montWy. Records were
kept of symptoms, weight, glycosuria, proteinuria and
blood-sugar levels (Autoanalyzer-ferricyanide method).
Periodically blood was taken for full blood count in-
cluding platelet number and morphology, serum bilirubin
(total and direct), prothrombin index, serum alkaline
phosphatase, serum transaminases (glutamic pyruvic and
glutamic oxaloacetic), serum lactic dehydrogenase and
blood urea. Urine specimens were examined microscopi-
cally as well as chemically.
The degree of control was assessed by the blood- and
urine-sugar levels, broadly according to criteria laid down
in the manufacturers' test sheets:
Excellent: 2-hour postprandial blood-sugar level below
140 mg. / lOOm!. and no glycosuria.
Good: 2-hour level below 160 mg./lOO m!. and slight
glycosuria.
Fair: 2-hour level below 200 mg.! 100 m!. and moderate
glycosuria.
Poor: 2-hour level below 260 mg./100 m!. and heavy
glycosuria.
Failure: No response to the preparation used.
RESULTS
The responses in the 86 patients were: excellent-21
(24%); good-·20 (23%); fair-21 (24%); poor-16 (19%);
and failed-8 (10%).
Among the 41 patients whose response was excellent or
good, the daily dose was 2·5 mg. in 2, 5 mg. in 19, 10 mg.
in 17 and 15 mg. in 3. A single daily dose was used in
all except 2 patients who took 5 mg. thrice daily. Among
the 21 patients whose response was fair, the daily dose
was 2·5 mg. in 1, 5 mg. in 7, 7t mg. in 1, 10 mg. in 8,
15 mg. in 3 and 20 mg. in 1. Three patients took 15 or
20 mg. in 2 or 3 divided doses. Among the 24 patients
whose response was poor or who were failures, the daily
dose was 5 mg. in 1, 10 mg. in 13 and 15 mg. in 10.
Eight patients took 5 mg. thrice daily.
Response was unrelated to age. There were some dif-
ferences in efficacy related to sex and race but they were
of doubtful significance. Response was related to dura-
tion of diabetes as indicated in Table I. Excellent or good
results were noted in two-thirds of patients whose dura-
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tion of diabete was le s than one year and who in the
main had not been treated previously; of those who e
duration of disea e was longer and who had been treated
with other agents, such results were obtained in one-third.
TABLE I. RELATIONSHIP BETWEE RESPO SE TO HB419
AND DURATIO ' OF DIABETES
No. of patients with duration of
diabetes of:
1 -12 1-5 6 -10
Response mOlllhs years years
Excellent or good 23 (68%) II (34%) 7 (35°~)
Fair 5 (15%) 9 (28%) 7 (35'l~)
Poor or failed 6 (17~~) 12 (38%) 6 (30 0 0 )
Totals 34 (100%) 32 (IOO~~) 20 (IOOO~)
In 31 patients it was possible to compare, on a tablet-
for-tablet basis, the efficacy of H8419 (5 mg.) with that
of tolbutamide (500 mg.) or chlorpropamide (_ 0 mg.). In
13 comparisons with tolbutamide H8419 was superior in
2 and equal in 11. In 18 comparisons with chlorpropamide
HB419 was inferior in 8 and equal in 10. In 7 compari-
sons (3 with tolbutamide and 4 with chlorpropamide) in
which no difference wa found, the results were equally
poor rather than equally good.
Side-effects and Toxicity
Mo t patients tolerated HB419 well. A generalized ery-
thematous rash occurred in I case and an itchy maculo-
papular eruption in another, while a third complained of
pruritus. In all 3 the reaction disappeared (topical corti-
costeroid and calamine lotion were used in the second
and third cases, respectively) despite continuing treatment
with H8419. One patient developed hypoglycaemia which
was relieved by oral sucrose, one became dizzy and one
complained of marked nausea and vomiting. Twenty
(23%) patients gained between 5 and 16 lb. weight while
on HB419 therapy. There was at lea t one heavy drinker
in the series and he did not complain of alcohol
intolerance.
Most of the renal, hepatic and haematological investi-
gations yielded normal results. There were slight rises in
the levels of serum lactic dehydrogenase in 4 cases, of
glutamic oxaloacetic acid transaminase in 4 patients and
of .!!lutamic pyruvrc transaminase in 2. A mild elevation
of the serum bilirubin level occurred in the heavy drinker.
Pretreatment levels of serum lactic dehydrogenase, glu-
tamic oxaloacetic transaminase, glutamic pyruvic trans-
aminase and bilirubin were raised in 5, 1, 1 and 2 patients,
respectively, and all returned to normal during the cour e
of HB419 therapy. In 2 cases low pretreatment blood
neutrophil counts became normal after treatment with
HB419 was started.
DISCUSSION
A number of ulphonylureas are available for the treat-
ment of maturity-onset diabetes, and the introduction of
a new one should be justified by evidence of uperiority
in respect of potency, toxicity or side-effects. The minute-
ness of the dosage of HB419 is interesting pharmacologi-
calfy but does not necessarily confer therapeutic
advantages.
There is no doubt that HB419 is an effective hypogly-
caemic agent. In the rather severe test provided by our
Indian and Bantu diabetics, excellent or good results were
achieved in nearly half the cases and a fair response in a
further quarter. Furthermore, it is possible that even
better results might have been obtained by using larger
doses. Thus the total daily dose did not exceed 5 mg. in
a third of patients whose response was classified as fair,
or 10 mg. in more than half of those in the poor
or failed category.
On the other hand, evidence was not obtained that
HB419 has significant advantages over the other sulpho-
nylureas in common use. This was reflected in the relatively
small proportion of good results achieved in diabetics
of some years' standing, most of whom had previously
been treated with other sulphonylureas, and also
in the direct comparisons between HB419 and tolbuta-
mide or chlorpropamide. These comparisons were neither
randomized nor 'blind', but the results indicated that, on
a tablet-for-tablet basis, HB419 was occasionally better
than tolbutamide but not uncommoo!y inferior to chlor-
propamide. The toxicity of HB419 appeared to be low, but
it was not free of side-effects including hypoglycaemia
and weight gain. The latter is a well-recognized accom-
paniment of sulphonylurea therapy and its frequency in
our patients was possibly related to the absence of strict
dietary control.
It is possible that with larger doses and in patients
more amenable to dietary control HB419 would achieve
results better than those reported here. In particular, it
needs to be systematically compared with chlorpropamide,
the most potent of the sulphonylureas currently in use.
SUMMARY
HB419 or glibenclamide, a new sulphonylurea, was used in the
treatment of 86 Indian and Bantu maturity-onset diabetics. The
response was excellent or good in 47%, fair in 24% and poor
or absent in 29%. Results were better in new diabetics than in
older cases previously treated with other sulphonylureas. On a
tablet-far-tablet basis it was more effective than tolbutamide in
2 out of 13 patients, but less active than chlorpropamide in
8 out of 18. Toxicity was low, and side-effects were uncommon
except for gain in weight. It is suggested that larger doses in
patients more amenable to strict dietary control may yield beller
results.
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